Activin-actrii antagonists and uses for treating bone and other disorders
US-2015283209-A1 · Oct 8, 2015 · US
Activin-actriia antagonists and uses for treating multiple myeloma
US9572865B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9572865-B2 |
| Application number | US-201213460342-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 30, 2012 |
| Priority date | Nov 23, 2005 |
| Publication date | Feb 21, 2017 |
| Grant date | Feb 21, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.
First claim
Opening claim text (preview).
We claim: 1. A method for treating multiple myeloma in a human patient, the method comprising administering to the patient an effective amount of an ActRIIa-Fc fusion protein, wherein the fusion protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:3, and wherein the fusion protein binds to activin and/or GDF11. 2. The method of claim 1 , wherein the ActRIIa-Fc fusion protein comprises the amino acid sequence of SEQ ID NO:3. 3. The method of claim 1 , wherein the ActRIIa-Fc fusion protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:2. 4. The method of claim 1 , wherein the ActRIIa-Fc fusion protein comprises the amino acid sequence of SEQ ID NO:2. 5. The method of claim 1 , wherein the ActRIIa-Fc fusion protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:7. 6. The method of claim 1 , wherein the ActRIIa-Fc fusion protein comprises the amino acid sequence of SEQ ID NO:7. 7. The method of claim 6 , wherein the N-terminus of the ActRIIa-Fc fusion protein is ILGRSETQE (SEQ ID NO:11). 8. The method of claim 1 , wherein the ActRIIa-Fc fusion protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:12. 9. The method of claim 1 , wherein the ActRIIa-Fc fusion protein comprises the amino acid sequence of SEQ ID NO:12. 10. The method of claim 1 , wherein the N-terminus of the ActRIIa-Fc fusion protein is ILGRSETQE (SEQ ID NO:11). 11. The method of claim 1 , wherein the ActRIIa-Fc fusion protein comprises one or more modified amino acids selected from: a glycosylated amino acid, a PEGylated amino acid, a farnesylated amino acid, an acetylated amino acid, a biotinylated amino acid, or an amino acid conjugated to a lipid moiety. 12. The method of claim 1 , wherein the ActRIIa-Fc fusion protein is glycosylated and has a glycosylation pattern obtainable from a Chinese hamster ovary cell. 13. The method of claim 1 , wherein the ActRIIa-Fc fusion protein binds to activin. 14. The method of claim 13 , wherein the ActRIIa-Fc fusion protein binds to activin A. 15. The method of claim 13 , wherein the ActRIIa-Fc fusion protein binds to activin B. 16. The method of claim 13 , wherein the ActRIIa-Fc fusion protein binds to GDF11. 17. The method of claim 1 , wherein the ActRIIa-Fc fusion protein binds to GDF11.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9572865B2 cover?
- In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.
- Who is the assignee on this patent?
- Knopf John, Seehra Jasbir, Kumar Ravindra, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/3061. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 9 related publications on this page (citations in our corpus or others sharing the same primary CPC).